Comparing of MediWound Ltd. (MDWD) and Kura Oncology Inc. (NASDAQ:KURA)

MediWound Ltd. (NASDAQ:MDWD) and Kura Oncology Inc. (NASDAQ:KURA), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 3.34M 30.74 5.27M -0.21 0.00
Kura Oncology Inc. N/A 0.00 59.78M -1.63 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of MediWound Ltd. and Kura Oncology Inc.


Table 2 has MediWound Ltd. and Kura Oncology Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
MediWound Ltd. -157.78% -31.9% -2.9%
Kura Oncology Inc. 0.00% -40% -35.5%

Volatility & Risk

MediWound Ltd.’s current beta is 0.73 and it happens to be 27.00% less volatile than S&P 500. Kura Oncology Inc.’s 165.00% more volatile than S&P 500 volatility due to the company’s 2.65 beta.


MediWound Ltd. has a Current Ratio of 6.7 and a Quick Ratio of 6.3. Competitively, Kura Oncology Inc.’s Current Ratio is 13.8 and has 13.8 Quick Ratio. Kura Oncology Inc.’s better ability to pay short and long-term obligations than MediWound Ltd.

Analyst Ratings

The next table highlights the given recommendations and ratings for MediWound Ltd. and Kura Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 3 3.00
Kura Oncology Inc. 0 0 0 0.00

MediWound Ltd.’s upside potential currently stands at 208.73% and an $11.67 consensus price target.

Insider & Institutional Ownership

MediWound Ltd. and Kura Oncology Inc. has shares owned by institutional investors as follows: 36.4% and 84.8%. MediWound Ltd.’s share owned by insiders are 41.5%. Competitively, 11.6% are Kura Oncology Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -7.45% -6.05% -6.25% -23.01% -29.84% 7.14%
Kura Oncology Inc. -5.07% 8.34% 11.88% 34.28% -5.29% 14.67%

For the past year MediWound Ltd. has weaker performance than Kura Oncology Inc.


MediWound Ltd. beats Kura Oncology Inc. on 7 of the 10 factors.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.